Due to an update to medical necessity guidelines by National Imaging Associates (NIA Magellan), patient access to Centinel Spine’s prodisc® L Lumbar Total Disc Replacement (TDR) system has increased to an additional 9.2 million covered lives.
NIA Magellan provides third-party prior authorization services to U.S. insurers. Nine major commercial payors that follow NIA Magellan’s clinical coverage guidelines have now started to cover lumbar TDR, including BCBS of Florida and South Carolina, Harvard Pilgrim and Tufts, among others. prodisc L remains the only lumbar TDR device that is FDA approved for two-level use.
“This recent announcement of expanded coverage for lumbar TDR demonstrates the important progress being made in this area,” said Centinel Spine CEO Steve Murray. “We are encouraged that NIA Magellan recognizes the large body of clinical evidence that demonstrates lumbar TDR to be a safe and effective procedure for select patients. This coverage expansion represents an excellent opportunity for surgeons to provide more patients with a broader spectrum of treatment options and ensure the delivery of the best spine care possible.”
Due to an update to medical necessity guidelines by National Imaging Associates (NIA Magellan), patient access to Centinel Spine's prodisc® L Lumbar Total Disc Replacement (TDR) system has increased to an additional 9.2 million covered lives.
NIA Magellan provides third-party prior authorization services to U.S. insurers. Nine major...
Due to an update to medical necessity guidelines by National Imaging Associates (NIA Magellan), patient access to Centinel Spine’s prodisc® L Lumbar Total Disc Replacement (TDR) system has increased to an additional 9.2 million covered lives.
NIA Magellan provides third-party prior authorization services to U.S. insurers. Nine major commercial payors that follow NIA Magellan’s clinical coverage guidelines have now started to cover lumbar TDR, including BCBS of Florida and South Carolina, Harvard Pilgrim and Tufts, among others. prodisc L remains the only lumbar TDR device that is FDA approved for two-level use.
“This recent announcement of expanded coverage for lumbar TDR demonstrates the important progress being made in this area,” said Centinel Spine CEO Steve Murray. “We are encouraged that NIA Magellan recognizes the large body of clinical evidence that demonstrates lumbar TDR to be a safe and effective procedure for select patients. This coverage expansion represents an excellent opportunity for surgeons to provide more patients with a broader spectrum of treatment options and ensure the delivery of the best spine care possible.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
